Jan 23, 2026
3 min read
A new CPHI report looks at how the ethical integration of AI, the redesign of supply chains and fair access to medicines will define the industry's success this year
The pharmaceutical industry is changing its approach to adapt to an increasingly demanding environment.In one of the world's most innovative sectors, the company is moving away from traditional models and focusing on agile management and technology.and the pressure to achieve more sustainable and equitable access to medicines.
One of the most striking aspects of the report is the rapid adoption of artificial intelligence in this field. From research and discovery of new medicines to optimization of production and clinical care, the changing characteristics of processes all look set to continue well into 2026. However, CPHI says its use raises regulatory and ethical questions that the sector will face.
The need for clear regulatory frameworks;strict controls to ensure data protection;ethical use of AI;and patient safety have become industry priorities.In particular, the report notes that the US, Europe and China are already developing specific regulations, although there is still a gap between technological innovation and regulatory acceptance.
The report points to the key factors that will be stimulated in the coming years, especially highlighting the role of digitalisation, the new regulatory framework and the pressure to achieve greater sustainability and equity of access to medicines.
This is another of the conclusions of the CPHI analysis, as it ensures that in the global context of 2026, marked by political tensions, conflicts and the climate crisis affecting pharmaceutical supply chains, the world's major powers will seek to reduce their dependence on third countries for the production of raw materials and medicines.
Therefore, the process points to the creation of regional and regional areas in Europe, Asia and America to reduce the risk regardless of the political and economic situation.However, CPHI warns that this plan will increase the cost of production and distribution, which can be transferred to the price of medicine.
According to the report, another area that will be important in the pharmaceutical industry in 2026 is sustainability.Recognized for its environmental impact, from greenhouse gas emissions to chemical waste production, it is under pressure to adopt more responsible practices.Among the advances highlighted in the report are green chemistry, bio-based materials and circular economy principles, and the regulation of hazardous chemicals such as PFAS.
In this sense, CPH highlights that artificial intelligence can help reduce environmental impact, improving production and logistics processes.Although they also warn that it is not without challenges, as data centers and technical infrastructure consume large amounts of energy and generate electronic waste.
The industry will have to demonstrate that its profitability is matched by real environmental commitments and closing the gap in access to medicines.
The medical panorama that CPHI envisions for 2026 is one of great technological progress, but also legal, economic and social.Therefore, the company will find a balance between innovation and service, ensuring that its products are accessible, sustainable and safe.
Global cooperation, ethical and transparent rules for artificial intelligence, and a commitment to sustainability are key factors in addressing this situation.It is not enough to implement technological development in isolation; it is important to promote international relations in order to speed up research and standardize legal criteria for health problems.
Finally, the industry must demonstrate that profit is compatible with a real commitment to the environment and a reduction in the gap in access to medicines, ensuring that scientific progress is left behind and responding to the demands of a more informed and demanding society.
* The content is prepared by journalists specializing in the field of health and approved by a committee of senior experts.However, we recommend that the reader consult a health professional with any health questions.
